Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

Blood

Volumn 111, Issue 8, 2008, Pages 4355-4364

  Gontarewicz, Artur ^a   Balabanov, Stefan ^a   Keller, Gunhild ^a   Colombo, Riccardo ^b   Graziano, Alessio ^b   Pesenti, Enrico ^b   Benten, Daniel ^a   Bokemeyer, Carsten ^a   Fiedler, Walter ^a   Moll, Jürgen ^b   Brümmendorf, Tim H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; BCR ABL PROTEIN; CRK LIKE PROTEIN; HISTONE H3; IMATINIB; PHA 739358; AURORA KINASE; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; BENZAMIDE DERIVATIVE; CD34 ANTIGEN; DNA; MUTANT PROTEIN; NUCLEAR PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CD34 SELECTION; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA CONTENT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GENE; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T315I GENE; WESTERN BLOTTING; WILD TYPE; ANIMAL; CELL CYCLE G2 PHASE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MITOSIS; MUTATION; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD34; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; G2 PHASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MITOSIS; MUTANT PROTEINS; MUTATION; NUCLEAR PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 43249111278     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-113175     Document Type: Article

References (34)

1. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABLoncogene. Se-min Hematol. 2003;40:4-10.
2. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653.
3. O'Brien SG, Guilhot F. Larson RA, et al. Imatinib compared with Interferon and low-dose cytara-bine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
4. White DL. Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006; 108:697-704.
5. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
6. Sawyers CL; Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
7. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003; 101:4611-4614.
8. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN 107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
9. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305: 399-401.
10. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7:129-141.
11. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66:11314-11322.
12. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev. 2006;16:92-99.
13. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842-854.
14. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr Opin Gell Biol. 2003;15:672-683.
15. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumori-genesis. Cancer Metastasis Rev. 2003;22:451-464.
16. Andrews PD. Aurora kinases: shining lights on the therapeutic horizon? Oncogene. 2005;24: 5005-5015.
17. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4: 927-936.
18. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10:262-267.
19. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006;66:1007-1014.
20. Giles FJ, Cortes J, Jones D, Bergstrom D, Kan- tarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007;109:500-502.
21. Fancelli D, Moll J, Varasi M, et al. 1,4,5,6-tetrahy- dropyrrolo[3.4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem. 2006:49:7247-7251.
22. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood. 2004;103:523-529.
23. Balabanov S, Gontarewicz A, Ziegler P, et al. Hy- pusination of eukaryotic initiation factor 5A (elF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood. 2007;109:1701 -1711.
24. Paquette L, Shah NR Sawyers CL, et al. PHA-739358. an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T3151 mutations of BGR-ABL [abstract]. Blood. 2007;108(Suppl 1):1030.
25. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319-325.
26. von Bubnoff N, Manley PW. Mestan J, Sanger J, Peschel G, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006; 108:1328-1333.
27. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006; 108:2332-2338.
28. Cheetham GM, Charlton PA, Golec JM, Pollard JR. Structural basis for potent inhibition of the Aurora kinases and a T315l multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett. 2007;251:323-329.
29. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006;66:10959-10966.
30. Fiskus W, Pranpat M, Balasis M, et al. Cotreat-ment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib rnesylate-sensitive or irnatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2006;12:5869-5878.
31. Fiskus W, Pranpat M, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006;108:645-652.
32. Ditchfield C; Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1. Mad2. and Cenp-E to kineto- chores. J Cell Biol. 2003;161:267-280.
33. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol. 2003;161: 281-294.
34. Modugno M, Casale E, Soncini C, et al. Crystal structure of the T3151 Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res. 2007;67:7987-7990.